NL-OMON22245
Completed
Not Applicable
HIgh-dose baclofen for the treatment of alcohol addiction: A double-blind, randomized, placebo-controlled study.
Academisch Medisch Centrum (AMC)0 sites160 target enrollmentTBD
Conditionsalcohol dependence (AD)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- alcohol dependence (AD)
- Sponsor
- Academisch Medisch Centrum (AMC)
- Enrollment
- 160
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male and Female patients, aged between 18\-60 years;
- •2\. Participants have a current DSM\-IV diagnosis of alcohol dependence;
Exclusion Criteria
- •1\. Participants with current severe psychiatric disorders (schizophrenia, schizoaffective disorder,bulimia/anorexia, or ADHD requiring medication) besides depression, bipolar disorder and anxiety;
- •2\. Participants with serious medical illnesses (Parkison’s disease, gastric ulcer, duodenal ulcer, cerebrovascular disease, respiratory insufficiency, hepatic or renal insufficiency, and epilepsy);
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
High-dose baclofen for the treatment of alcohol addiction * A double-blind, randomized, placebo-controlled studyverslavingaddictionNL-OMON41310Academisch Medisch Centrum130
Active, not recruiting
Not Applicable
High-dose baclofen for the treatment of alcohol addictioEUCTR2011-004142-17-NLAcademic Medical Centrum250
Active, not recruiting
Not Applicable
Baclofen for the Treatment of Alcohol Dependence - BACLADEUCTR2010-021861-62-DECharité - Universitätsmedizin Berlin
Unknown
Phase 4
Baclofen in Managing Acute Alcohol WithdrawalAlcohol Use DisorderAlcohol WithdrawalNCT03293017Universitair Ziekenhuis Brussel90
Completed
Phase 4
Baclofen as Add-On to Standard Treatment of Alcohol- Dependent PatientsAlcohol DependenceNCT01002105Sha'ar Menashe Mental Health Center75